CClinicalTrials.gg
RecruitingNCT07580014Updated May 12, 2026

Choroidal and Retinal Features in PACD and POAG on OCT and OCTA

An observational study in Glaucoma, OCTA and Choroid, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Observational

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 2 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
132
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Glaucoma is a group of irreversible, progressive optic neuropathies that can lead to severe visual field defects and even blindness, affecting nearly 95 million people worldwide. Based on anterior chamber angle structure, glaucoma is classified into primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG). Although POAG is more common, PACG is more severe and more likely to cause blindness if not managed appropriately. Globally, PACG accounts for approximately 25% of all glaucoma cases but is responsible for roughly 50% of glaucoma-related blindness. Generally, the term "glaucoma" implies optic nerve damage; however, glaucomatous optic neuropathy may be absent in subacute and acute angle-closure glaucoma. Therefore, according to international consensus, primary angle-closure disease is categorized as PACD-encompassing primary angle-closure suspect (PACS), primary angle closure (PAC), and PACG-based on the extent of angle closure, intraocular pressure elevation, and optic nerve damage. With advances in ophthalmic imaging, an increasing array of diagnostic modalities has been applied to glaucoma diagnosis. Optical coherence tomography (OCT), which utilizes low-coherence light to display cross-sectional images of the retina in vivo, represents a rapid, non-invasive, and continuously evolving imaging method. Building upon OCT, OCTA has emerged as a novel imaging technique that allows non-invasive visualization and assessment of blood flow in individual retinal layers [5]. Existing OCT and OCTA research on glaucoma primarily focuses on the optic disc and macula of glaucoma patients, providing evidence of changes in the retinal nerve fiber layer, macular ganglion cell thickness, optic nerve head structure, and peripapillary and macular vasculature. Other studies have examined choroidal vascular architecture and thickness in glaucoma; previous findings from our research group also indicate that choroidal vascular density is significantly lower in eyes with POAG and PACG compared to normal eyes, while choroidal stromal area is significantly greater in PACG than in POAG eyes and normal controls. Further investigation into choroidal and retinal alterations in glaucoma is warranted. Consequently, the OCT and OCTA fundus characteristics of patients with PACD and POAG remain an area with unexplored unknowns. This study utilizes OCT and OCTA to observe the choroidal and retinal tissue structure and vascular hemodynamics in patients with PACD and POAG, aiming to comprehensively investigate structural changes in the glaucomatous fundus, broaden new research directions, and explore and supplement the understanding of glaucoma pathogenesis.

02

Conditions studied

  • Glaucoma
  • OCTA
  • Choroid

Browse trials for

03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's planned enrollment of 132 is above the median of 103 across 454 observational studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 159 studies on the registry; 77 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study includes an observation cohort of adults diagnosed with POAG or PACD and a control cohort of healthy adults without glaucoma. Eligible participants range in age from 18 to 90 years and have no history of confounding retinal or neurological diseases that would interfere with OCT/OCTA imaging assessment.

Inclusion criteria

  • Control group: Healthy individuals with no history of ocular surgery, IOP \< 21 mmHg, and CDR \< 0.5 bilaterally without asymmetry
  • Observation group: Glaucoma specialist-confirmed diagnosis of POAG or PACD (per ISGEO staging: PACS/PAC/PACG)

Exclusion criteria

Exclusion Criteria:

  • History of retinal or macular disease (e.g., AMD, DR, RVO, ERM)
  • Non-glaucomatous optic neuropathy (e.g., MS, NMO)
  • Poor OCT/OCTA image quality
  • Refusal to sign informed consent
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
132 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control Group

    Inclusion Criteria: 1. Individuals undergoing routine physical examination, generally in good health, with no history of prior surgery. 2. No use of glaucoma medications, no evidence of elevated intraocular pressure (IOP \< 21 mmHg), no significant optic nerve head (ONH) asymmetry (cup-to-disc ratio difference \< 0.2), and cup-to-disc ratio (CDR) \< 0.5 in both eyes. 3. Age between 18 and 90 years, inclusive; any gender. Exclusion Criteria: 1. Known history of retinal disease, including any condition involving macular degeneration (e.g., age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, viral retinitis, or epiretinal membrane). 2. Optic nerve abnormalities other than glaucoma, such as those associated with neurological complications (e.g., Multiple Sclerosis, Neuromyelitis Optica). 3. Poor quality of OCT or OCTA images obtained post-examination. 4. Refusal to sign the informed consent form.

  • Observation Group

    Inclusion Criteria: 1. Confirmed diagnosis of Primary Open-Angle Glaucoma (POAG) or Primary Angle-Closure Disease (PACD) by a glaucoma specialist. The diagnosis of POAG is based on standard clinical criteria, specifically: presence of an open angle, glaucomatous optic neuropathy, current or past elevation of intraocular pressure, and visual field defects \[10\]. PACD cases are diagnosed and enrolled according to the clinical staging system of PACS, PAC, and PACG as established by the International Society of Geographical and Epidemiological Ophthalmology (ISGEO) . 2. Age between 18 and 90 years, inclusive; any gender. Exclusion Criteria: 1. Known history of retinal disease, including any condition involving macular degeneration (e.g., age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, viral retinitis, or epiretinal membrane). 2. Optic nerve abnormalities other than glaucoma, such as those observed in patients with neurological com

06

What researchers measure

Primary outcomes

  1. Subfoveal choroidal thickness (μm)

    Subfoveal choroidal thickness (SFCT) is defined as the vertical distance between the outer border of the retinal pigment epithelium (RPE)/Bruch's membrane complex and the choroid-scleral junction directly beneath the fovea centralis. This measurement is obtained using a widefield swept-source OCT device, which enables enhanced depth imaging and high-resolution visualization of the choroid.The assessment is subsequently conducted by a masked, experienced grader using the integrated caliper tool. SFCT serves as a quantitative biomarker for choroidal structural changes associated with primary angle-closure disease (PACD) and primary open-angle glaucoma (POAG).

    Time frame: Day 1

  2. Deviation of the horizontal watershed zone

    The deviation of the horizontal watershed zone (HWZ) is assessed by determining whether the HWZ is displaced superiorly or inferiorly relative to the fovea centralis. This evaluation is performed using 24 × 20 mm en face OCTA images acquired with a widefield swept-source OCTA device. All measurements are carried out with the device's built-in caliper tool by a masked, experienced grader. The HWZ deviation serves as a quantitative indicator reflecting alterations in choroidal venous outflow patterns.

    Time frame: Day 1

Secondary outcomes

  1. Choroidal vascularity index (%)

    Choroidal vascularity index (CVI) is defined as the ratio of choroidal vascular volume to total choroidal volume within a designated region, expressed as a percentage, with higher values indicating greater vascular density. The measurement was performed on images acquired with a widefield swept-source OCTA deviceand assessed by a masked, experienced grader.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • Zhongshan Ophthalmic Center, Sun Yat-sen University
    Guangzhou, Guangdong 510060, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07580014
Lead sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Jul 16, 2024
Primary completion
Apr 20, 2027 (estimated)
Completion
Apr 20, 2027 (estimated)
Last update
May 12, 2026

Study contacts

Yuheng Tan
Contact
tanyuhesper@163.com
+02066615461

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion